Durstewitz, Daniel
Koppe, Georgia
Meyer-Lindenberg, Andreas
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01ZX1311A, 01ZX1314G, 01ZX1314G)
Deutsche Forschungsgemeinschaft (Du 354/8-2, Du 354/10-1)
EC | Seventh Framework Programme (602805, 602450)
Article History
Received: 5 June 2018
Revised: 2 January 2019
Accepted: 24 January 2019
First Online: 15 February 2019
Compliance with ethical standards
:
: AML has received consultant fees from Boehringer Ingelheim, Elsevier, Walt Disney Pictures, Brainsway, Lundbeck Int. Neuroscience Foundation, Sumitomo Dainippon Pharma Co., Academic Medical Center of the University of Amsterdam, Synapsis Foundation-Alzheimer Research Switzerland, IBS Center for Synaptic Brain Dysfunction, Blueprint Partnership, University of Cambridge, Dt. Zentrum für Neurodegenerative Erkrankungen, Universität Zürich, L.E.K. Consulting, ICARE Schizophrenia, Science Advances, and has received fees for lectures, interviews and travels from Lundbeck International Foundation, Paul-Martini-Stiftung, Lilly Deutschland, Atheneum, Fama Public Relations, Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Jansen-Cilag, Hertie Stiftung, Bodelschwingh-Klinik, Pfizer, Atheneum, Universität Freiburg, Schizophrenia Academy, Hong Kong Society of Biological Psychiatry, Fama Public Relations, Spanish Society of Psychiatry, Reunions I Ciencia S.L., Brain Center Rudolf Magnus UMC Utrecht. The other authors declare that they have no conflict of interest.